We emphasize that while COL3A1, SPP1, and PLAU show promise as biomarkers for distinguishing between different stages of esophageal cancer, further prospective studies with stage-specific validation, ideally using clinical samples, are required to substantiate their role in early detection and patient management. This evidence concerns the gene PLAU and esophageal cancer.